Mayo Clinic Laboratory and Pathology Research Roundup: July 29
The research roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.
Precursors of pancreatic cancer arise in the ductal epithelium; markers exfoliated into pancreatic juice might be used to detect high-grade dysplasia (HGD) and cancer. Specific methylated DNA sequences in pancreatic tissue have been associated with adenocarcinoma. We analyzed these methylated DNA markers (MDMs) in pancreatic juice samples from patients with pancreatic ductal adenocarcinomas (PDACs) or intraductal papillary mucinous neoplasms (IPMNs) with HGD (cases), and assessed their ability to discriminate these patients from individuals without dysplasia or with IPMNs with low-grade dysplasia (IPMN-LGD) (controls).
Published to PubMed This Week
- Phosphodiesterase 10A IgG: A Novel Biomarker of Paraneoplastic Neurologic Autoimmunity.
- Role of BNP vs NT-proBNP Testing in the Age of New Drug Therapies: Sacubitril-Valsartan.
- Dysproteinemia and the Kidney: Core Curriculum 2019.
American Journal of Kidney Disease
- Predictors of Extensive Lymphatic Dissemination and Recurrences in Node-Positive Endometrial Cancer.
- Single-Nucleotide Polymorphisms Sequencing Identifies Candidate Functional Variants at Prostate Cancer Risk Loci.
- Robust Hierarchical Density Estimation and Regression for Re-stained Histological Whole Slide Image Co-registration.
- Whole Genome Mate-pair Sequencing of Plasma Cell Neoplasm as a Novel Diagnostic Strategy: A Case of Unrecognized t(2;11) Structural Variation.
Clinical Lymphoma, Myeloma, and Leukemia